Patents by Inventor Jeffrey Browning

Jeffrey Browning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10494416
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 3, 2019
    Assignees: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Publication number: 20180273605
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: September 27, 2018
    Applicants: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Patent number: 9650430
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: May 16, 2017
    Assignee: BIOGEN, MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Publication number: 20150139992
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: August 6, 2014
    Publication date: May 21, 2015
    Applicants: TOPOTARGET SWITZERLAND SA, BIOGEN IDEC MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Patent number: 8828669
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: September 9, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Patent number: 8709759
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: April 29, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Konrad Miatkowski, Werner Meier
  • Patent number: 8142779
    Abstract: Therapeutic uses of inhibitors of the lymphotoxin pathway to treat tumors, specifically to treat follicular lymphomas.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: March 27, 2012
    Assignees: Biogen Idec MA Inc., New York University
    Inventors: Jeffrey Browning, Jeanette Thorbecke, Vincent Tsiagbe
  • Publication number: 20110002924
    Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
    Type: Application
    Filed: April 7, 2010
    Publication date: January 6, 2011
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
  • Publication number: 20100260761
    Abstract: The present invention relates to antibodies that bind Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: June 5, 2006
    Publication date: October 14, 2010
    Applicants: BIOGEN, INC., THE FACULTY OF MEDICINE OF THE UNIV. OF GENEVA
    Inventors: Jeffrey Browning, Yves Chicheportiche
  • Publication number: 20100233179
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Application
    Filed: September 30, 2009
    Publication date: September 16, 2010
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Patent number: 7731963
    Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: June 8, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
  • Publication number: 20100136625
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Application
    Filed: August 17, 2009
    Publication date: June 3, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey BROWNING, Konrad MIATKOWSKI, Werner MEIER
  • Publication number: 20100136000
    Abstract: Therapeutic uses of inhibitors of the lymphotoxin pathway to treat tumors, specifically to treat follicular lymphomas.
    Type: Application
    Filed: October 13, 2009
    Publication date: June 3, 2010
    Applicants: NEW YORK UNIVERSITY, BIOGEN IDEC MA INC.
    Inventors: Jeffrey BROWNING, Jeanette THORBECKE, Vincent TSIAGBE
  • Patent number: 7695934
    Abstract: Nucleic acids that encode Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, are described.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: April 13, 2010
    Assignees: Biogen Idec MA Inc., The Faculty of Medicine of the University of Geneva
    Inventors: Jeffrey Browning, Yves Chicheportiche
  • Patent number: 7585946
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 8, 2009
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Konrad Miatkowski, Werner Meier
  • Patent number: 7566769
    Abstract: Tumor Necrosis Factor Related Ligand (TRELL) polypeptides, a novel member of the tumor necrosis factor family (TNF) and compositions comprising them are disclosed.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: July 28, 2009
    Assignees: Biogen Idec MA Inc., The Faculty of Medicine of the University of Geneva
    Inventors: Jeffrey Browning, Yves Chicheportiche
  • Publication number: 20090087403
    Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
    Type: Application
    Filed: October 8, 2008
    Publication date: April 2, 2009
    Inventors: Jeffrey BROWNING, Maryann PUGLIELLI, Rafi AHMED
  • Publication number: 20080210721
    Abstract: An apparatus for folding and storing articles of clothing is provided, and the apparatus comprises a relatively flat sheet having opposing ends, a topside and a bottomside. The apparatus has at least one aperture that serves as a handle on one end and an extended portion on the opposing end. The extended portion is bendable from about 0 degrees to about 90 degrees, and the extended portion serves as a support for the articles of clothing when the articles are folded and stacked atop the topside surface of the sheet.
    Type: Application
    Filed: March 1, 2007
    Publication date: September 4, 2008
    Inventors: John Cammarano, Jeffrey Browning, Dan M. DeLaRosa
  • Publication number: 20080008714
    Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
    Type: Application
    Filed: March 20, 2007
    Publication date: January 10, 2008
    Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
  • Patent number: D563165
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: March 4, 2008
    Assignee: Pragotrade, Inc.
    Inventors: Victor Robert Younger, Robert Jeffrey Browning, Jeffrey William Palese